Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals
Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux[®], Decubal[®], Lactocare[®], Apobase[®], Dailycare[®] and Fludent[®] from Teva Pharmaceuticals (Teva) for a total consideration of EUR 84m.The transaction transfers ownership of the brand portfolio, comprised of Flux[®], Decubal[®], Lactocare[®], Apobase[®], Dailycare[®] and Fludent[®] from Teva to Karo. The brands generated sales just short of EUR 35m in 2020 on a global basis. The majority is generated in the Nordic markets, including Scandinavia, where the brands already are